278 related articles for article (PubMed ID: 14968327)
1. [Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion].
Ruzicka T; Trompke C
Hautarzt; 2004 Feb; 55(2):165-70. PubMed ID: 14968327
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis.
van de Kerkhof PC; Berth-Jones J; Griffiths CE; Harrison PV; Hönigsmann H; Marks R; Roelandts R; Schöpf E; Trompke C
Br J Dermatol; 2002 Mar; 146(3):414-22. PubMed ID: 11952541
[TBL] [Abstract][Full Text] [Related]
3. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
Lecha M; Mirada A; López S; Artés M;
J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
[TBL] [Abstract][Full Text] [Related]
4. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial.
Veien NK; Bjerke JR; Rossmann-Ringdahl I; Jakobsen HB
Br J Dermatol; 1997 Oct; 137(4):581-6. PubMed ID: 9390335
[TBL] [Abstract][Full Text] [Related]
5. Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety.
Van de Kerkhof PC; Werfel T; Haustein UF; Luger T; Czarnetzki BM; Niemann R; Plänitz-Stenzel V
Br J Dermatol; 1996 Nov; 135(5):758-65. PubMed ID: 8977677
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris.
Miyachi Y; Ohkawara A; Ohkido M; Harada S; Tamaki K; Nakagawa H; Hori Y; Nishiyama S
Eur J Dermatol; 2002; 12(5):463-8. PubMed ID: 12370136
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients.
Andreassi L; Giannetti A; Milani M;
Br J Dermatol; 2003 Jan; 148(1):134-8. PubMed ID: 12534607
[TBL] [Abstract][Full Text] [Related]
8. Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice.
Lambert J; Trompke C
Dermatology; 2002; 204(4):321-4. PubMed ID: 12077538
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
Feldman SR; Mills M; Brundage T; Eastman WJ
J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of efficacy and safety of calcipotriol versus tacalcitol ointment, both in combination with NBUVB phototherapy in the treatment of stable plaque psoriasis.
Dua I; Aggarwal K; Jain VK
Photodermatol Photoimmunol Photomed; 2017 Sep; 33(5):275-281. PubMed ID: 28602032
[TBL] [Abstract][Full Text] [Related]
11. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas.
Ortonne JP; Humbert P; Nicolas JF; Tsankov N; Tonev SD; Janin A; Czernielewski J; Lahfa M; Dubertret L
Br J Dermatol; 2003 Feb; 148(2):326-33. PubMed ID: 12588387
[TBL] [Abstract][Full Text] [Related]
12. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream.
Nakayama J
Eur J Dermatol; 2000; 10(7):528-32. PubMed ID: 11056423
[TBL] [Abstract][Full Text] [Related]
13. Profile of clinical efficacy and safety of topical tacalcitol.
Leone G; Pacifico A
Acta Biomed; 2005 Apr; 76(1):13-9. PubMed ID: 16116820
[TBL] [Abstract][Full Text] [Related]
14. High-concentration (20 mug/g) tacalcitol ointment therapy on refractory psoriasis vulgaris with low response to topical corticosteroids.
Katayama I; Ohkawara A; Ohkido M; Harada S; Tamaki K; Nakagawa H; Hori Y; Nishiyama S
Eur J Dermatol; 2002; 12(6):553-7. PubMed ID: 12459526
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp.
Green C; Ganpule M; Harris D; Kavanagh G; Kennedy C; Mallett R; Rustin M; Downes N
Br J Dermatol; 1994 Apr; 130(4):483-7. PubMed ID: 8186114
[TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled evaluation of the irritant potential of tacalcitol (1a,24-dihydroxyvitamin D3) in healthy volunteers.
Schlotmann K; Ortland C; Neumann NJ; Ruzicka T; Lehmann P
Contact Dermatitis; 2000 May; 42(5):260-3. PubMed ID: 10789839
[TBL] [Abstract][Full Text] [Related]
17. Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study.
Helfrich YR; Kang S; Hamilton TA; Voorhees JJ
Br J Dermatol; 2007 Aug; 157(2):369-74. PubMed ID: 17596167
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: "right-left intra-individual pre/post comparison design".
Brazzelli V; Barbagallo T; Prestinari F; Rona C; De Silvestri A; Trevisan V; Borroni G
Int J Immunopathol Pharmacol; 2005; 18(4):755-60. PubMed ID: 16388725
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
Eichenfield LF; Ganslandt C; Kurvits M; Schlessinger J
Pediatr Dermatol; 2015; 32(1):28-35. PubMed ID: 25412565
[TBL] [Abstract][Full Text] [Related]
20. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
